NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free ALRN Stock Alerts $3.30 -0.11 (-3.23%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$3.20▼$3.3850-Day Range$3.30▼$7.0952-Week Range$1.01▼$7.42Volume28,199 shsAverage Volume73,501 shsMarket Capitalization$71.25 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aileron Therapeutics alerts: Email Address Aileron Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside475.8% Upside$19.00 Price TargetShort InterestHealthy1.26% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 6 Articles This WeekInsider TradingSelling Shares$138,719 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.62) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector675th out of 932 stocksPharmaceutical Preparations Industry316th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingAileron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAileron Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Aileron Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.26% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 89.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALRN. Previous Next 1.8 News and Social Media Coverage News SentimentAileron Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $138,719.00 in company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by Institutions90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aileron Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aileron Therapeutics are expected to decrease in the coming year, from ($0.62) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aileron Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Aileron Therapeutics Stock (NASDAQ:ALRN)Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Read More ALRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALRN Stock News HeadlinesMay 2, 2024 | insidertrades.comInsider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 10,746 Shares of StockMay 24, 2024 | americanbankingnews.comAtreca (NASDAQ:BCEL) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head ContrastMay 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | msn.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q1 2024May 15, 2024 | tmcnet.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 15, 2024 | globenewswire.comAileron Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 6, 2024 | globenewswire.comAileron Therapeutics to Present at Two Upcoming Investor ConferencesMay 3, 2024 | seekingalpha.comALRN Aileron Therapeutics, Inc.May 3, 2024 | finance.yahoo.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 3, 2024 | globenewswire.comAileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 MillionMay 2, 2024 | finance.yahoo.comAileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trialMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 MillionMay 1, 2024 | globenewswire.comAileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)April 16, 2024 | investorplace.comALRN Stock Earnings: Aileron Therapeutics Reported Results for Q4 2023April 16, 2024 | finanznachrichten.deAileron Therapeutics, Inc.: Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 15, 2024 | globenewswire.comAileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | markets.businessinsider.comAileron Therapeutics CEO Manuel Aivado Steps Down; Names Brian Windsor ReplacementMarch 12, 2024 | globenewswire.comAileron Therapeutics Announces CEO TransitionFebruary 15, 2024 | finance.yahoo.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 15, 2024 | globenewswire.comAileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader EventFebruary 1, 2024 | finance.yahoo.comAileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024January 30, 2024 | msn.comAileron Therapeutics Announces Director Nomination DetailsJanuary 30, 2024 | msn.comAileron Therapeutics Announces 2024 Annual Meeting PlansDecember 27, 2023 | benzinga.comAileron Therapeutics Stock (NASDAQ:ALRN) Dividends: History, Yield and DatesDecember 15, 2023 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 0.43%See More Headlines Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today5/29/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+479.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.55% Return on Assets-31.15% Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book1.58Miscellaneous Outstanding Shares21,590,000Free Float20,387,000Market Cap$70.82 million OptionableNot Optionable Beta2.32 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. James Brian Windsor Ph.D. (Age 58)CEO, President & Director Comp: $715.92kKey CompetitorsPDS BiotechnologyNASDAQ:PDSBUnity BiotechnologyNASDAQ:UBXCumberland PharmaceuticalsNASDAQ:CPIXMersana TherapeuticsNASDAQ:MRSNVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsTexas Capital Bank Wealth Management Services IncBought 10,398 shares on 5/13/2024Ownership: 0.155%Of Texas/Texas Am I UniversitySold 20,315 sharesTotal: $85,526.15 ($4.21/share)Of Texas/Texas Am I UniversitySold 10,746 sharesTotal: $53,192.70 ($4.95/share)James Brian WindsorBought 225 shares on 12/15/2023Total: $758.25 ($3.37/share)James Brian WindsorBought 5,076 shares on 11/20/2023Total: $9,999.72 ($1.97/share)View All Insider TransactionsView All Institutional Transactions ALRN Stock Analysis - Frequently Asked Questions Should I buy or sell Aileron Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALRN shares. View ALRN analyst ratings or view top-rated stocks. What is Aileron Therapeutics' stock price target for 2024? 1 analysts have issued 1 year price targets for Aileron Therapeutics' stock. Their ALRN share price targets range from $19.00 to $19.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 475.8% from the stock's current price. View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts. How have ALRN shares performed in 2024? Aileron Therapeutics' stock was trading at $3.05 at the start of the year. Since then, ALRN shares have increased by 8.2% and is now trading at $3.30. View the best growth stocks for 2024 here. Are investors shorting Aileron Therapeutics? Aileron Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 256,900 shares, an increase of 89.0% from the April 30th total of 135,900 shares. Based on an average daily volume of 90,500 shares, the days-to-cover ratio is currently 2.8 days. Currently, 1.3% of the company's stock are short sold. View Aileron Therapeutics' Short Interest. When is Aileron Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our ALRN earnings forecast. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its earnings results on Monday, May, 20th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.72. When did Aileron Therapeutics' stock split? Aileron Therapeutics's stock reverse split on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV). When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. Who are Aileron Therapeutics' major shareholders? Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Texas Capital Bank Wealth Management Services Inc (0.16%). Insiders that own company stock include James Brian Windsor and Of Texas/Texas Am I University. View institutional ownership trends. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALRN) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star4 Cryptos BETTER than BitcoinTrue Market InsidersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
